Heavy regulatory scrutiny and public skepticism regarding drug
safety is largely due to the widely publicized health risks of popular
arthritis painkillers. A large contributor to this doubt: The belief
that television commercial advertising downplays harmful side effects
caused by drugs.
As a repercussion, more and more drug makers are taking a step
back from advertising their drugs on television and searching for
new methods to reach consumers. In fact, TAP
Pharmaceuticals has pulled a nearly $100-million TV advertisement
campaign for Prevacid to focus on print ads that more easily explain
the potential side effects and health risks. (Johnson
& Johnson has voluntarily made the switch as well.)
According to a TAP spokeswoman, print advertising allows consumers
to take their time reviewing the risk-benefit information; it also
gives the company more room to include that information.
FDA Taking a Stand?
As far as misleading, faulty drug advertising on television is
concerned, the Food and Drug Administration (FDA) has been showing
signs it will watch ads more closely:
-
The agency asked Bayer Pharmaceuticals and its marketing partners
to pull a 15-second version of their television ad that promotes
the erectile dysfunction drug Levitra. Why? The FDA said the
ad did not include certain safety information and made a misleading
claim about how Levitra compares with other drugs in the same
class.
-
The agency made Pfizer pull ads for Viagra for similar reasons.
Forbes
April 19, 2005
Pittsburgh Post-Gazette April 19, 2005
Chicago
Tribune April 19, 2005 (Registration Required)
|